CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.19 USD
+0.02 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.18 -0.01 (-0.84%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 61 - 80 ( 158 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Catalysts Near-Term; Solid Balance Sheet; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Data Updates for CX-2009 Ahead in 2H:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Lead PDCs in Ph 2s; Two More Assets into Clinic in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Year-End 2020 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ?2029 Cohorts Kickoff; ?2009 Study Redesigned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial CX-2009 and CX-2029 Phase 2 Data Expected in Late 2021; 3Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Expansion Cohorts Should Expand Value
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R